Gilead Sciences (GILD) Net Equity Issued and Repurchased (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Net Equity Issued and Repurchased data on file, last reported at $166.0 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 34.13% year-over-year to $166.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $322.0 million (down 39.02% YoY) and the FY2025 annual result came in at $408.0 million, down 3.32% from the prior year.
• Net Equity Issued and Repurchased improved to $166.0 million in Q1 2026, from $32.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $252.0 million in Q1 2025 to a low of $3.0 million in Q2 2022.
• A 5-year average of $90.4 million and a median of $94.0 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased soared 1366.67% — and 2023, when it tumbled 85.23%.
• Tracing GILD's Net Equity Issued and Repurchased over 5 years: stood at $176.0 million in 2022, then plunged by 85.23% to $26.0 million in 2023, then jumped by 565.38% to $173.0 million in 2024, then plunged by 81.5% to $32.0 million in 2025, then soared by 418.75% to $166.0 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $166.0 million (Q1 2026), $32.0 million (Q4 2025), and $97.0 million (Q3 2025), per Business Quant data.